ArticleEmerging infectious diseases2002
Antimicrobial resistance of Escherichia coli O26, O103, O111, O128, and O145 from animals and humans.
Article in Emerging infectious diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Epidemiological insights into virulence and antimicrobial resistance ofFrontiers in veterinary science · 2026Article
- Genotypic Profiling of Virulence and Antibiotic Resistance Genes ofInternational journal of microbiology · 2026Article
- Comprehensive analysis of Escherichia coli in bovine urinary tract infections: serotypes, antibiotic resistance, and virulence gene profiles.Scientific reports · 2025Article
- Role of Lysogenic Phages in the Dissemination of Antibiotic Resistance Genes Applied in the Food Chain.Foods (Basel, Switzerland) · 2025Review
- Epidemiology and molecular characterisation of multidrug-resistant Escherichia coli isolated from chicken meat.PloS one · 2025Article
- Isolation, and Identification ofInfection and drug resistance · 2024Article
- Molecular Detection of Tetracycline-Resistant Genes in Multi-Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Comparative genetic characterization of CMY-2-type beta-lactamase producing pathogenic Escherichia coli isolated from humans and pigs suffering from diarrhea in Korea.Annals of clinical microbiology and antimicrobials · 2023Article
- Prevalence and Implications of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2022Review
- Prevalence, Antibiogram, and Multidrug-Resistant Profile ofFrontiers in veterinary science · 2022Article
- Predominance of genetically diverse ESBL Escherichia coli identified in resistance mapping of Vembanad Lake, the largest fresh-cum-brackishwater lake of India.Environmental science and pollution research international · 2021Article
- Antibiotic Susceptibility Profiles and Frequency of Resistance Genes in Clinical Shiga Toxin-Producing Escherichia coli Isolates from Michigan over a 14-Year Period.Antimicrobial agents and chemotherapy · 2021Article
- Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2021Review
- Protected but not from Contamination: Antimicrobial Resistance Profiles of Bacteria from Birds in a Ghanaian Forest Protected Area.Environmental health insights · 2021Article
- Investigation of plasmid-mediated resistance inSaudi journal of biological sciences · 2020Article
- Prevalence and distribution of antimicrobial resistance determinants of Escherichia coli isolates obtained from meat in South Africa.PloS one · 2020Article
- Antimicrobial Drug-Resistant Shiga Toxin-Producing Escherichia coli Infections, Michigan, USA.Emerging infectious diseases · 2017Article
- Role of antigen-43 on biofilm formation and horizontal antibiotic resistance gene transfer in non-O157 Shiga toxin producingIranian journal of microbiology · 2017Article
- Virulence factors, serogroups and antimicrobial resistance properties of Escherichia coli strains in fermented dairy products.BMC research notes · 2014Article
- Characterization of Shiga toxin-producing Escherichia coli isolated from ground beef collected in different socioeconomic strata markets in Buenos Aires, Argentina.BioMed research international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Susceptibilities to fourteen antimicrobial agents important in clinical medicine and agriculture were determined for 752 Escherichia coli isolates of serotypes O26, O103, O111, O128, and O145. Strains of these serotypes may cause urinary tract and enteric infections in humans and have been implicated in infections with Shiga toxin-producing E. coli (STEC). Approximately 50% of the 137 isolates from humans were resistant to ampicillin, sulfamethoxazole, cephalothin, tetracycline, or streptomycin, and approximately 25% were resistant to chloramphenicol, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanic acid. Approximately 50% of the 534 isolates from food animals were resistant to sulfamethoxazole, tetracycline, or streptomycin. Of 195 isolates with STEC-related virulence genes, approximately 40% were resistant to sulfamethoxazole, tetracycline, or streptomycin. Findings from this study suggest antimicrobial resistance is widespread among E. coli O26, O103, O111, O128, and O145 inhabiting humans and food animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.